Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Company announcement – No. 6/ 2021
Copenhagen, DK and Boston, MA, U.S., February 8, 2021 – Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL) (CVR-no. 20045078) a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.
Please see the attached files.
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of next generation peptide-based medicines that change the lives of people living with metabolic and gastrointestinal diseases. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development, and one candidate being reviewed for regulatory approval in the United States. Zealand markets V-Go®, an all-in-one basal-bolus insulin delivery option for people with diabetes. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics.
Zealand Pharma was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand Pharma’s business and activities, please visit www.zealandpharma.com.
The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.
For further information, please contact:
Zealand Pharma Investor Relations
Zealand Pharma Media Relations
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Adevinta ASA24.2.2021 23:18:27 CET | Press release
Adevinta ASA (ADE) - Adevinta further optimises its portfolio by divesting Yapo in Chile
Tenaris S.A.24.2.2021 23:00:26 CET | Press release
Tenaris Announces 2020 Fourth Quarter and Annual Results
Colliers International Group Inc.24.2.2021 22:31:35 CET | Press release
Colliers recognized as a 2021 Global Outsourcing 100® company
HEINEKEN NV24.2.2021 22:07:54 CET | Press release
HEINEKEN, The Coca-Cola Company and the Coca-Cola System in Brazil announce redesigned distribution partnership
Aalberts N.V.24.2.2021 21:16:30 CET | Press release
Aalberts N.V.: Aalberts accelerates strategy and continues investments and innovations; solid and resilient performance with strong free cash flow
Release24.2.2021 20:21:48 CET | Press release
Scatec ASA – Long term incentive programme
AMG Advanced Metallurgical Group N.V.24.2.2021 19:31:26 CET | Press release
AMG Announces Changes to the Composition of the Supervisory Board and Nominates Its CEO and COO for Reappointment When Their Current Terms End in May 2021
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom